Skip to content

Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma

A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01739465
Enrollment
120
Registered
2012-12-03
Start date
2012-11-30
Completion date
Unknown
Last updated
2013-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Keywords

Cholangiocarcinoma, Pathologic, Digestive System, Neoplasms, Neoplasms by Site, Digestive System Diseases, Bile Duct Diseases, Biliary Tract Diseases, Pathological Conditions, Constriction, Adenocarcinoma, Carcinoma

Brief summary

The purpose of this study is to compare endoscopic radiofrequency ablation with photodynamic therapy for inoperable cholangiocarcinoma

Interventions

PROCEDURESelf expanding metallic stent (SEMS)

Self expanding metallic stent

PROCEDUREEndoscopic radiofrequency ablation (ERFA)

Endoscopic radiofrequency ablation

Photodynamic therapy

Sponsors

Guangzhou Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old * Pathologically or radiologically confirmed biliary malignant * Inoperability by staging

Exclusion criteria

* Cholangiocarcinoma with widespread metastasis * Coagulopathy (INR \> 2.0 or prothrombin time \> 100 sec or platelet count \< 50,000) * Prior SEMS placement * Pregnancy * Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3 ) * Life expectancy \< 3months

Design outcomes

Primary

MeasureTime frame
stent patency6 months

Secondary

MeasureTime frame
overall survival rate3 years

Countries

China

Contacts

Primary ContactHuihong Liang, MD
beanth@163.com+86-20-34153043

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026